Business
Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million","length":311,"tagName":"p"},{"type":"text","content":"Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024","length":156,"tagName":"p"},{"type":"text","content":"As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US","length":539,"tagName":"p"},{"type":"text","content":"Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar","length":183,"tagName":"p"},{"type":"text","content":"REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register","length":141,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / August 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2025 financial results.","length":208,"tagName":"p"},{"type":"text","content":"2025 SECOND QUARTER COMPANY FINANCIAL RESULTS:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net Prescription Products Revenue: The combined net revenue for the Company's prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1) was approximately $2.9 million in the second quarter of 2025, representing an increase of approximately 36% over the combined net revenue in the first quarter of 2025, which totaled approximately $2.2 million, and an i...